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ABSTRACT 
Objective: This study was performed in order to estimate clinical effectiveness of antibiotic therapy in acute and recurrent obstructive bronchitis. 
For estimation the following was used: the Fishbern method of antibiotics distribution according to clinical effectiveness levels with the help of 
weighted coefficients and classical “cost–efficiency” pharmacoeconomic analysis of the given antibiotic therapy. Then, for the first time ever, the 
obtained results of both methods were combined.  
Methods: Materials were presented by the data on antibiotic therapy, given for patients who were hospitalized to the in-patient medical facilities due to 
acute or recurrent obstructive bronchitis. Medical records of 2 259 patients were included in the study. The patients were 0 to 18 y old. In order to 
determine the weighed coefficients of each used antibiotic with subsequent distribution according to the levels of clinical effectiveness the Fishbern 
method was applied. Three levels of clinical effectiveness were used in this study, i.e. high, medium and low. The “cost–efficiency” pharmacoeconomic 
analysis was applied to combine costs and efficiency of the compared therapy courses in acute and recurrent obstructive bronchitis.  
Results: Finally we found out that the highest probability of positive effect of cephalosporins group agents was associated with the use of 
Cefotaximum. (Biosynthesis). From the pharmacoeconomic point of view the most effective in treating acute and recurrent obstructive bronchitis in 
children in the in-patient facilities was Ceftriaxonum (Synthesis). Out of protected penicillins group, we used Amoxicillin/clavulanic acid–original 
drug Augmentin (Smithkline Beecham Pharmaceuticals) and generic drug Amoxiclav (Lek d. d). Augmentin effectiveness was 0.591, and Amoxiclav 
effectiveness–0.530. Cost of Augmentin treatment course was 106.26 rub. (1.68 US$), cost of Amoxiclav treatment course–103.50 rub.(1.63 US$). 
Augmentin use turned out to be the most reasonable. Augmentin treatment course was characterized by lower ICER coefficient versus Amoxiclav. 
We found out that from the pharmacoeconomic point of view Azitromicin (Vertex Ltd.) treatment turned out to be the most reasonable of the whole 
macrolides antibiotics for treatment of acute and recurrent obstructive bronchitis. However, according to the Fishbern clinical effectiveness 
classification this antibiotic belonged to the group with medium effectiveness level. The group with high effectiveness level included Sumamed, 
Azitral, Hemomicin, Clacid, Zitrocin and Clabax. Clacid and Clabax were excluded during the pharmacoeconomic analysis. The highest value of ICER 
coefficient was obtained for Sumamed and made up 39,367.50 rub. (621.53 US$). The highest level of clinical effectiveness was characteristic for 
Sumamed as well. Besides Sumamed was an original drug of azitromicin. According to the obtained data Azitral and Hemomicin had the lowest 
values of ICER coefficient (1151.67 rub. (18.18 US$) and 1812.22 rub. (28.61 US$) respectively). Therefore based on the clinical economic analysis 
these medical agents turned out to be the most suitable.  
Conclusion: The results of the pharmacoeconomic analysis showed that the most effective drugs in treatment of acute and recurrent obstructive 
bronchitis in children in in-patient facilities appeared to be the following: out of cephalosporins-Ceftriaxonum (Synthesis), out of protected 
penicillins-Augmentin (Smithkline Beecham Pharmaceuticals), out of macrolides-Azitromicin (Vertex Ltd.). According to the Fishbern classification, 
these drugs belonged to the group with medium level of effectiveness. 
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Acute obstructive bronchitis (AOB)-a widespread disease that 
affects 10-15% of the child population and is characterized by the 
growing incidence worldwide. A considerable number of young 
children (over 50%) due to acute respiratory infections (ARI) may 
be repeated episodes of obstructive bronchitis [1]. In cases of 
repeated (2-3 times or more during the year) of cases of bronchitis 
with a bronchoostructive syndrome (BOS) is formed by recurrent 
obstructive bronchitis (ROB). In many cases, bronchial asthma (BA) 
is the cause of a recurrence of obstructive bronchitis (OB). 
INTRODUCTION 
Currently, there is a constant increase in the incidence of BA and the 
growing severity of the disease. Often, asthma in children is formed 
in early childhood. This problem is actualized [2]. It is now 
established, that the microbe-viral association, where in one of the 
infectious agents are intracellular pathogens, such as, Chlamydia 
pneumoniae, Mycoplasma pneumoniae, Legionella spp. et al., play an 
important role in the formation of bronchial obstructive diseases 
and can cause exacerbation of their [3]. Therefore, the problem of 
the treatment of bacterial infections in patients with obstructive 
syndrome is important. Among these patients, concomitant diseases 
are often observed, such as, rhinitis, sinusitis, tonsillitis and otitis. 
An important objective in therapy is to determine the clinical 
effectiveness of drugs and schemes of treatment. The problem is of 
particular importance due to the wide range of drugs, as well as a 
significant number of generic drugs. Comparison of the clinical 
effectiveness of original and generic drugs is possible by distribution 
of drugs over the so-called levels of clinical effectiveness. 
Fishburne's method can be used for this purpose. It is mathematics 
method. 
Also, currently a pharmacoeconomic analysis (PEA) of drug therapy 
is a fundamental and determinant direction of the planning and 
definition of medical measures. Using the results of PEA can 
streamline the system of prescribing of drugs, to eliminate 
appointment of unnecessary drugs. Comparative evaluation of the 
quality of two or more methods of prevention, diagnostics, drug and 
non-drug treatment is a major technique of PEA. 
The aim of the study was to evaluate the clinical effectiveness of 
antibiotic treatment of AOB and ROB, namely the distribution of 
antibiotics in levels of clinical efficiency with the help of weighting 
coefficients by method of Fishburne, and classic PEA of conducted 
antibiotic therapy, as well as a comparison of the results obtained by 
both methods, which was conducted for the first time. 
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Further, incremental cost for using more expensive methods of 
treatment was estimated, if more effective schemes of treatment 
corresponded larger direct medical costs. Incremental costs (the 
cost of the additional effect of using alternative methods of 
treatment “B” instead of the method «A») are calculated as:  
MATERIALS AND METHODS 
Materials for the study were data on antibiotic therapy of patients 
admitted to hospitals of medical organizations with AOB or ROB. The 
study included 2 259 patients. The age of patients ranged from 0 to 
18 y old. 
In order to determine the weighting factors of each of the used 
antibiotics with their subsequent distribution on levels of clinical 
efficiency was used Fishburne' method. In this study three levels of 
clinical efficiency used-namely high, medium and low. 
The analysis of "cost-effectiveness" was applied for compare the cost 
and effectiveness courses of therapy of OB. For each alternative 
scheme of treatment СЕR (cost-effectiveness ratio) was calculated of 
the formula:  
СЕR= DC/E, where 
СЕR — ratio of «cost/effectiveness»;  
DC — direct medical costs;  
E — effectiveness of treatment 
ICER= (C2-C1)/(E2-E1
ICER-incremental cost-effectiveness ratio, 
), where  





method of treatment «А», 
2
E
–effectiveness of method of treatment «В», 
1-effectiveness of method of treatment «А». 
Three groups of antibiotics: cephalosporins, penicillins and 
macrolides were used for the treatment of AOB and ROB in the 
analyzed period. The largest number of appointments accounted for 
injectable cephalosporins-57.8%.  
RESULTS  
Cefotaxim (56.9%), ceftriaxon (23%), cefuroxim (13.8%), cefazolin 
(6.3%) were used from the cephalosporin antibiotics (table 
 
1). 
Table 1: The structure of the cephalosporin antibiotic prescriptions 
Cefotaxim Ceftriaxon 23%   56.9% Cefazolin 6.3% Cefuroxim 13.8% 
 Cefotaxim Ceftriaxon  Claforan Lendaсin  Cefazolin Axetin 
92.1%  7.9%  86.7%  13.3%  100%  100 %  
Amoxicillin/clavulanic acid (Augmentin, Amoxiclav) was used in 16.3% of appointments of the group of protected penicillins. Macrolides were used 
in 25.9%. Antibiotics-macrolides were used such as azithromycin (65.6%), clarithromycin (9.5%), spiramycin (18,9%), midecamycin (6%) (table 2). 
 










Azithromycin Azithral Zithrocin Sumamed Hemomycin  Clacid Fromilid Clabax Macropen Rovamycin 
17.8% 15.2% 7.0% 37.8% 22.2% 15.4% 41.0%  43.6% 100% 100% 
 
The largest numbers of cases of highly effective antibiotic therapy of 
AOB, ROB (the clinical effect of “recovery”) were observed with use 
of macrolides. Clinical effects, such as "significant improvement" and 
"recovery" were noted for the cephalosporins and protected 
penicillins in the presence of co-morbidities in patients with AOB, 
ROB, such as otitis, sinusitis, tonsillitis, often accompanied by fever, 
intoxication. 
 








  Cefotaxim  0.630   
 0.537 Claforan 
Ceftriaxon 
 
Ceftriaxon  0.546 
 Lendaсin  0.214 
Cefazolin  0.140 Cefazolin 
Cefuroxim Axetin  0.512   
Amoxicillin/Clavulanic acid  Augmentin  0.591 
Amoxiclav  0.530 
Azithromycin  0.947 Azithromycin 
Sumamed  0.980 
Azithral  0.976 
Zithrocin  0.957 





Clacid  0.969 
Clabax  0.951 
Fromilid  0.948 
Spiramycin  0.920 Rovamycin 
Macropen Midecamycin  0.850 
* represented as a fraction of 
Low efficiency of cephalosporins and protected penicillins in the 
treatment of AOB and ROB in the absence of concomitant diseases may 
indicate an allergic, viral or atypical nature of the AOB and ROB, since 
AOB and ROB are often developed in patients with ARI (table 3) 
a unit 
Each antibiotic xi  (i=1,n) is associated with an assessment of its 


















system of weights was build observing the following conditions 
 
Where; ai–is the weight of i-th antibiotic, i-number of antibiotic, n-
quantity of 
All antibiotics were placed by rank of factor (table 4), i.e. in order of 
decreasing their significance (in our case-clinical 
antibiotics. 
effectiveness
.21 ni xxxx 
) 
 …… (1) 









 weights were 
determined by Fishburne's scale (table 5). 
……….. (2) 
Fishburne's rule reflects the fact that about the level of significance 
of indicators do not know anything except (1). Then the estimate by 
the formula (2) corresponds to the maximum entropy cash 
information uncertainty about the object of research. 
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Table 4: Ranking of antibiotics by the clinical effectiveness 
Clinical effectiveness Antibiotic Rank of factor, a i 
Sumamed  0.980 1 
Azithral  0.976 2 
Hemomycin  0.970 3 
Clacid  0.969 4 
Zithrocin  0.957 5 
Clabax  0.951 6 
Fromilid  0.948 7 
 0.947 Azithromycin 8 
 0.920 Rovamycin 9 
Macropen  0.850 10 
 0.630 Cefotaxim 11 
Augmentin  0.591 12 
Ceftriaxon  0.546 13 
 0.537 Claforan 14 
Amoxiclav  0.530 15 
Axetin  0.512   16 
Lendaсin   0.214 17 
 0.140 Cefazolin 18 
 
Table 5: Weight coefficients of antibiotics calculated by the 
Fishburne method 
Rank of factor, 
ai 
Antibiotic  Weight coefficients of 
antibiotics calculated by the 
Fishburne method 
Sumamed 1 0.105 
Azithral 2 0.099 
Hemomycin 3 0.094 
Clacid 4 0.088 
Zithrocin 5 0.082 
Clabax 6 0.076 
Fromilid 7 0.070 
8 Azithromycin 0.064 
9 Rovamycin 0.058 
Macropen 10 0.053 
11 Cefotaxime 0.047 
Augmentin 12 0.041 
Ceftriaxone 13 0.035 
14 Claforan 0.029 
Amoxiclav 15 0.023 
Axetin 16   0.018 
Lendaсin  17 0.012 
18 Cefazolin 0.006 
 
Then all the antibiotics were distributed by levels of clinical 
effectiveness (high, medium and low).  
The largest weight coefficient, calculated on the criteria of 
Fishburne, was put at the highest level. For low level a maximum 
weight coefficient
d = (value of high level-value of low level)/2 (3) 
, divided by three, is assigned (the number of 
levels). After that, the value of d-step formula, which is calculated as 
the difference between the high level and low level, divided in half, 
was defined. The index of the average level is equal to the lower 
level, increased on step by the formula (3). 
Thus, in the calculations the boundaries of levels of clinical 
effectiveness of antibiotics in the treatment of AOB/ROB were 
defined:  
high-0,071-0,105; medium-0,036-0,070; low-





macrolides, such as Sumamed, Azithral, Hemomycin, Clacid, 
Zithrocin, Clabax (table 6). 
Table 6: Classification of antibiotics by levels of clinical 
efficiency 





















After the distribution of antibiotics on levels of clinical effectiveness 
by the method of Fishburne PEA was held for used antibiotics. 
 
As a basic pharmacoeconomic indicator was calculated coefficient 
"cost-effectiveness", showing which costs are necessary to achieve 
unit of efficiency (in this case, one cured patient) with treatment by 
compare antibiotics (table 7). 
 
Table 7: CER coefficient for the antibiotic of cephalosporin series, used in the treatment of AOB and ROB 
Antibiotic 
(trade name, manufacturer) 
The cost of the course, rub. (US$) CER, rub. (US$) The effectiveness of treatment 
Cefotaxim 190.94 (3.01) , Biosynthesis 0.630  303.08 (4.78) 
Claforan 1 427.80 (22.50) , Sotex 0.537  2 658.85 (41.98) 
Ceftriaxon, Synthesis 114.97 (1.82) 0.546  210.57 (3.32) 
Lendaсin, Sandoz GmbH 1 399.72 (22.10) 0.214  6 540.75 (103.26) 
Cefazolin 1 954.88 (30.86) , Sandoz GmbH 0.140  13 963.43 (220.45) 
Axetin 811.75 (12.82) , Medochemie, Ltd 0.512  1 585.45 (25.03) 
 
Calculation of the CER was performed by finding the ratio between 
the average cost of a course of antibiotic treatment to its 
effectiveness
Ef–
 (the probability of a positive clinical effect) 
CER=DC/Ef 
Where, DC-direct medical costs, 
the effectiveness of the treatment (relative amount of cured 
patients).  
The most expensive of the cephalosporin antibiotics is Cefazolin 
(Sandoz GmbH). The effectiveness of its is 0.140. The course of 
Ceftriaxone (Synthesis) is the least expensive. It costs 114.97 rub. 
(1.82 US$) with an effectiveness
Cefotaxim (Biosynthesis) has the most probability to offensive the 
positive clinical effect. In this case we used the coefficient ICER for 
determining cost (C) required to achieve one unit of efficiency (E). A 
compared course of antibiotics divide by the effectiveness and 
calculates the ICER for each pair of alternatives (table 8). 
 of 0.546. 
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Antibiotic 
Table 8: Calculation of the ratio of ICER 
Е С, rub. (US$) ΔЕ ΔС ICER, rub. (US$) 
0 0 0    
Cefazolin 0.140 , Sandoz GmbH 1 954.88 (30.86) 0.140 1 954.88 13 963.43 (220.45) 
Lendaсin, Sandoz GmbH 0.214 1 399.72 (22.10) 0.074 -556.16 -7 515.68 (118.66) 
Axetin 0.512 , Medochemie, Ltd 811.75 (12.82) 0.298 -587.97 -1 973.05 (31.15) 
Claforan, Sotex 0.537 1 427.80 (22.54) 0.025 616.05 24 642.00 (389.04) 
Ceftriaxon, Synthesis 0.546 114.97 (1.82) 0.009 -1 312.83 -145 870.00 (2 302.97) 
Cefotaxim, Biosynthesis 0.630 190.94 (3.01) 0.084 75.97 904.40 (14.28) 
 
For first variant of treatment comparison is carried out with the 
absence of antibiotic, for which the values of the cost and 
effectiveness will be zero. 
The negative value of the coefficient of ICER (such as, for Ceftriaxon) 
shows that the use in the treatment of AOB or ROB this antibiotic 
instead of the reference Claforan will achieve the best effect while 
reducing costs, and cost savings will amount to 145 870.00 rub. 
(2 302.97 US$) for unit of effectiveness
At this step 
. 
we excluded
After excluding we re-calculated the coefficient of increment (table 9).
 the courses of antibiotic therapy with low 
efficiency (Cefazolin, whose the effectiveness is 0.14 and Lendaсin, the 
effectiveness of which is 0.214); courses of antibiotic therapy with the 
highest values of the coefficient of increments (Claforan, for which 
ICER is 24 642.00 rub. (389.04 US$)), as well as courses of antibiotic 
therapy, when the coefficients of increment of costs for following them 
courses have negative values (Cefazolin, Lendaсin, Claforan). 
 
Antibiotic 
Table 9: Calculation of the ratio of ICER for cephalosporin antibiotics after exclusion 
Е С, rub. (US$) ΔЕ ΔС ICER, rub. (US$) 
  0 0       
Axetin 0.512 , Medochemie, Ltd 811.75 (12.82) 0.512 811.75 1 585.45 (25.03) 
Ceftriaxon, Synthesis 0.546 114.97 (1.82) 0.034 -696.78 -20 493.53 (323.55) 
Cefotaxim, Biosynthesis 0.630 190.94 (3.01) 0.084 75.97 904.40 (14.28) 
 
Table 10: CER coefficient for the protected penicillin antibiotics used in the treatment of AOB and ROB 
Antibiotic (trade name, manufacturer) The cost of the course, rub. (US$) CERThe effectiveness of treatment , rub. (US$) 
Augmentin (Smithkline Beecham Pharmaceuticals) 106.26 (1.68)  0.591   179.80 (2.84) 
 Amoxiclav (Lek d. d)  103.50 (1.63)  0.530 195.28 (3.08) 
 
Thus, as a result of the analysis obtained, that with a 
pharmacoeconomic standpoint Ceftriaxon (Synthesis) is the most 
effective in the treatment of AOB and ROB in children in hospital.  
Amoxicillin/clavulanic acid (the original drug is Augmentin 
(Smithkline Beecham Pharmaceuticals) and generic drug is 
Amoxiclav (Lek d. d)) were used from the group of protected 
penicillins. The effectiveness of Augmentin is 0.591, and the 
effectiveness of Amoxiclav-0.53. Price of Augmentin’course is 106.26 
rub. (1.68 US$), Amoxiclav’s course price-103.50 rub. (1.63 US$) 
(table 10). 
The most expedient is the use of Augmentin. Therapy of Augmentin 
is characterized by a lower value of the coefficient CER of relative 
Amoxiclav. 
Course of Clacid is the most expensive of the group of macrolides 
(clarithromycin, Abbott Laboratories)–896.00 rub. (14.15 US$). The 
least expensive is the course of Azithromycin, (Vertex Ltd.)-49.41 
rub. (0.78 US$). 
Sumamed (Pliva) has the highest probability of the positive clinical 
effect. In this case we use the coefficient ICER for determining cost 
(C) required to achieve one unit of effectiveness
For first variant of treatment comparison is carried out with the 
absence of antibiotic, for which the values of the cost and 
 (E). Compared 
courses of antibiotics rank by effectiveness and calculates the ICER 
to each pair of alternatives (table 11). 
effectiveness
Then, we excluded courses of antibiotic therapy with low 
 will be zero. 
effectiveness (Macropen, for which the efficiency is 0.850); courses 
of antibiotic therapy with the highest values of the coefficient of 
increments (From lid, for which ICER is 297 090.00 rub. (4 690.40 
US$) and Clacid-63 121.67 rub. (996.55 US$)), as well as courses of 
antibiotic therapy when the coefficients of increment costs following 
them rates are negative (Rovamycin
We re-calculated the coefficient of increment after excluding factors 
(table 12). 
, Fromilid, Clabax, Clacid). 
 
Antibiotic 
Table 11: Calculation of the ratio of ICER for antibiotics-macrolides 
Е С, rub. (US$) ΔЕ ΔС ICER, rub. (US$) 
0 0 0    
Macropen, KRKA 0.850 77.77 (1.23) 0.850 77.77 91.49 (1.44) 
Rovamycin 0.920 , Famar France 212.29 (3.35) 0.070 134.52 1 921.71 (30.34) 
Azithromycin 0.947 , Vertex Ltd. 49.41 (0.78) 0.027 -162.88 -6 032.59 (95.24) 
Fromilid, KRKA 0.948 346.50 (5.47) 0.001 297.09 297 090.00 (4 690.40) 
Clabax, Ranbaxy 0.951 291.24 (4.60) 0.003 -55.26 -18 420.00 (290.81) 
Zithrocin, Unique Pharma 0.957 138.54 (2.19) 0.006 -152.70 -25 450.00 (401.80) 
Clacid, Abbott Laboratories 0.969 896.00 (14.15) 0.012 757.46 63 121.67 (996.55) 
Hemomycin, Hemofarm Koncern A. D. 0.970 187.47 (2.96) 0.001 -708.53 -708 530.00 (11 186.14) 
Azithral, Shreya Life Sciences Pvt. Ltd 0.976 194.38 (3.07) 0.006 6.91 1 151.67 (18.18) 
Sumamed, Pliva 0.980 351.85 (5.55) 0.004 157.47 39 367.50 (621.53) 
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Antibiotic 
Table 12: Calculation of ICER for microcline antibiotics, after exclusion 
Е С, rub. (US$) ΔЕ ΔС ICER, rub. (US$) 
0 0 0       
Azithromycin 0.947 , Vertex Ltd. 49.41 (0.78) 0.947 49.41 52.18 (0.82) 
Zithrocin, Unique Pharma 0.957 138.54 (2.19) 0.010 89.13 8 913.00 (140.72) 
Hemomycin, Hemofarm Koncern A. D. 0.970 187.47 (2.96) 0.027 48.93 1 812.22 (28.61) 
Azithral, Shreya Life Sciences Pvt. Ltd 0.976 194.38 (3.07) 0.006 6.91 1 151.67 (18.18) 
Sumamed, Pliva 0.980 351.85 (5.55) 0.004 157.47 39 367.50 (621.53) 
 
Thus, we find, that the course of Azithromycin (Vertex Ltd.) from the 
pharmacoeconomic point of view, is the most appropriate of the 
antibiotics-macrolides in the treatment of AOB and ROB. However, 
the antibiotic according to the classification of the clinical 
effectiveness of Fishburne refers to the average level. Sumamed, 
Azitral, Hemomycin, Clacid, Zithrocin and Clabax belong to the high 
level of effectiveness
DISCUSSION  
. Clacid and Clabax were excluded from the PEA. 
The highest value ICER ratio was obtained for Sumamed and was 39 
367.50 rub. (621.53 US$). Sumamed is characterized of the highest 
value of clinical effectiveness. Besides Sumamed is original drug of 
azithromycin. Azitral and Hemomycin have the lowest values of ICER 
(1151,67 rub. (18.18 US$) and 1812.22 rub. (28.61 US$), 
respectively) after Azithromycin. Thus, these drugs are most suitable 
according to the results of clinical and economic analysis. 
Currently bronchitis treatment is often presented by the use of 
penicillins (amoxicillin, inhibitor-protected penicillins), II-III 
generation cephalosporins and macrolides [4, 5]. Today we observe 
the increase of infections, caused by β-lactamase-producing 
microorganisms, which destroy the β-lactam ring of penicillins and 
cephalosporins [6-8]. 
Nowadays the compounds, which inactivate the bacteria β-
lactamases, i.e. clavulanic acid (clavunat), sulbactam and 
tazobactam, are used in clinical practice. These compounds are 
called β-lactamase inhibitors [9, 10]. Very often due to their 
efficiency and low toxicity the cephalosporins are used in clinical 
practice. For example, cefotaxim and ceftriaxonum (III generation 
cephalosporins) are used in treatment of severe bronchitis forms. 
The ceftriaxonum pharmacokinetics, which allows taking the drug 
once daily, is the apparent advantage (half-life period of this 
antibiotic in children is 5-7 h) [11]. 
Today it is difficult both from the point of view of diagnostics and 
therapy to treat patients with recurrent broncho-obstructive 
diseases associated with “atypical” respiratory infections causative 
microorganisms (Chlamydia pneumoniae, Mycoplasma pneumoniae, 
etc.). Recently the atypical” causative microorganisms (Mycoplasma 
pneumoniae, Chlamydia pneumoniae, Legionella spp.) are often the 
etiology reasons of bacterial respiratory infections [12, 13]. 
Chlamydia and mycoplasmas contribute to broncho-obstruction 
development. Quite often in patients suffering from obstructive 
bronchitis and asthma a mixed infection is found (chlamydial and 
mycoplasmal) [14]. 
The etiological meaning of the “atypical” infections associated with 
asthma development is confirmed by the presence of specific IgE-
antibodies to Mycoplasma pneumoniae and Chlamydia pneumoniae 
[15-18]. 
The “atypical” infections contribute to the bronchi hyperactivity 
development and respiratory tract clearance mechanism 
deceleration. In its turn it leads to increase of micro-organisms 
capability to penetrate and distribute in the tissues, and to form a 
prolonged and chronic infection processes. For “atypical” infections 
treatment macrolides, tetracyclines and fluoroquinolones are used. 
The use of medical agents in pediatric practice should be combined 
with their maximal safety. In treatment of “atypical” infections in 
children only macrolides antibiotics are used. Today the most 
frequently used are 10-14 d courses of macrolides therapy [19, 20]. 
Only azitromicin is an exception: due to its pharmacokinetics this 
drug should be given for 3-5 d. In case of persistent “atypical” 
infection with concomitant recurrent broncho obstructive syndrome 
the most justified is the use of prolonged macrolides courses, 
“overlapping” 6-8 development cycles of the “atypical” micro-
organisms, such as Chlamydia [21, 22]. 
Currently the macrolides are considered the first-line agents for 
treatment of bronchitis in children, especially in case of β-lactam 
intolerance [23]. 
It is for the first time proposed to use in this study the Fishbern 
method for distribution of antibiotics, used in the in-patient 
treatment of acute and recurrent obstructive bronchitis forms in 
children, according to the clinical effectiveness levels as well as the 
classical “cost–efficiency” pharmacoeconomic method, which results 
in determination of the most suitable drugs for treatment from both 
clinical and economical points of view. The study results demostrate 
that the macrolide antibiotics possess high efficiency level according 
to Fishbern. Among them Sumamed (Pliva) has the highest value of 
clinical effectiveness (0.980). Besides Sumamed (Pliva) is an original 
azitromicin drug. Based on the PEA the most appropriate choice of 
the macrolide antibiotics is Azithromycin (Vertex Ltd.). This 
antibiotic possesses the medium efficiency level according to 
Fishbern. Azitral (Shreya Life Sciences Pvt. Ltd) and Hemomycin 
(Hemofarm Koncern A. D.) possess the lowest ICER coefficient values 
(1151, 67 rub. (18.18 US$) and 1812.22 rub. (28.61 US$), 
respectively) among the macrolides next to Azithromycin
CONCLUSION 
 (Vertex 
Ltd.). Clinical effectiveness value of Azitral (Shreya Life Sciences Pvt. 
Ltd) is 0.976, and clinical effectiveness value of Hemomycin 
(Hemofarm Koncern A. D.)–0.970. These antibiotics follow after 
Sumamed (Pliva) in the list of clinical effectiveness according to 
Fishbern. Therefore these drugs are the most suitable for treatment 
of AOB and ROB in children. 
As a result of PEA it was found that Ceftriaxon (Synthesis) is the the 
most effective cephalosporin in treatment of AOB and ROB in 
children in the hospital; from the group of protected penicillins–
Augmentin (Smithkline Beecham Pharmaceuticals), from the group of 
macrolide-Azithromycin (Vertex Ltd.). These drugs belong to the 
medium level of clinical efficiency determined using the Fishburne's 
method. 
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